retatrutide clinical trial results weight loss efficacy First phase 3 data, a Triumph of Science! retatrutide weight loss clinical results

Guevara-Campos, J., Gonzalez-Guevara, L., Parada, Y., and Urbaez-Cano, J

And this approach should only be considered by people already well-established on their GLP-1 dose with stable side effects and confident protein targets being met on normal days

Safety concerns : Important risks associated with GLP-1 receptor agonists include pancreatitis, gallbladder disease, dehydration leading to acute kidney injury, hypoglycaemia (when used with insulin or sulfonylureas), and potential worsening of diabetic retinopathy with rapid glycaemic improvement

Most mild symptoms improve with slower dose increases, smaller meals, hydration, and close follow-up